3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
2
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Hemorrhage
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Specimen Handling
5
Human Papillomavirus Recombinant Vaccine nonavalent
4
Papillomavirus Vaccines
3
Human Papillomavirus DNA Tests
3
Colposcopy
3
Radiotherapy, Intensity-Modulated
2
Methods
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Early Intervention, Educational
2
Cisplatin
2
human papillomavirus vaccine, L1 type 16, 18
1
artesunic acid
1
artenimol
1
artemisinin
1
adacel
1
Vaccines
1
Tetanus Toxoid
1
Sodium Chloride
1
Platinum
1
Patient Navigation
1
Nimorazole
1
Mass Screening
1
Interviews as Topic
1
Injections
1
High-Energy Shock Waves
1
Educational Status
1
Diphtheria-Tetanus-acellular Pertussis Vaccines
1
Diphtheria Toxoid
1
Clinical Protocols
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Papillomavirus Infections
×
Sodium Chloride
×
Clear all
NCT04199689
2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
6,033 enrolled